5-(trifluoromethyl)-1-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxylic Acid | 159885-87-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(trifluoromethyl)-1-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxylic Acid
• CAS: 159885-87-7
• 化学式: C₁₅H₇F₆N₃O₂S
• 分子量: 407.296
• InChiKey: VDZFSYWIDTXDQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  96.2
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  5-(trifluoromethyl)-1-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxylic Acid 、 3-二乙胺基丙胺 在 N,N'-羰基二咪唑 作用下， 生成 N-[3-(diethylamino)propyl]-5-(trifluoromethyl)-1-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxamide
  参考文献：
  名称：

  Novel Thiazole-Based Heterocycles as Selective Inhibitors of Fibrinogen-Mediated Platelet Aggregation

  摘要：

  The synthesis and biological activity of novel thiazole-based heterocycles as inhibitors of thrombin-induced human platelet aggregation are described. Further evaluation of selected compounds show they inhibit platelet aggregation as stimulated by a variety of agonists. The more active compounds also were found to inhibit fibrinogen binding to platelets. To further delineate the mechanism of action of these compounds, direct binding studies with the purified glycoprotein (GP) IIb/IIIa receptor were performed. Flow cytometry analyses of 24 and 32 indicate that these compounds block the activation process of the GPIIb/IIIa receptor without denaturing the integrin receptor. On the basis of these studies, 32 exhibited the best profile as a novel nonpeptide inhibitor of fibrinogen-mediated platelet aggregation.

  DOI：

  10.1021/jm00001a008
• 作为产物：
  描述：

  2-溴-4'-(三氟甲基)苯乙酮 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 7.0h， 生成 5-(trifluoromethyl)-1-[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]pyrazole-4-carboxylic Acid
  参考文献：
  名称：

  Novel Thiazole-Based Heterocycles as Selective Inhibitors of Fibrinogen-Mediated Platelet Aggregation

  摘要：

  The synthesis and biological activity of novel thiazole-based heterocycles as inhibitors of thrombin-induced human platelet aggregation are described. Further evaluation of selected compounds show they inhibit platelet aggregation as stimulated by a variety of agonists. The more active compounds also were found to inhibit fibrinogen binding to platelets. To further delineate the mechanism of action of these compounds, direct binding studies with the purified glycoprotein (GP) IIb/IIIa receptor were performed. Flow cytometry analyses of 24 and 32 indicate that these compounds block the activation process of the GPIIb/IIIa receptor without denaturing the integrin receptor. On the basis of these studies, 32 exhibited the best profile as a novel nonpeptide inhibitor of fibrinogen-mediated platelet aggregation.

  DOI：

  10.1021/jm00001a008

文献信息

• Bis-aryl thiazole derivatives
  申请人：Amaral Catherine M.

  公开号：US20050215608A1

  公开（公告）日：2005-09-29

  Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3. The subject compositions are particularly useful in the treatment of obesity and type II diabetes, and associated diseases.

  本发明提供的化合物、组合物和方法可用于治疗或预防由解偶联蛋白介导的病症或紊乱。特别是，本发明的化合物可调节 UCP3 的表达和/或活性。本发明组合物特别适用于治疗肥胖症和 II 型糖尿病及相关疾病。
• US7358267B2
  申请人：——

  公开号：US7358267B2

  公开（公告）日：2008-04-15
• [EN] BIS-ARYL THIAZOLE DERIVATIVES<br/>[FR] DERIVES DE BIS-ARYL THIAZOLE
  申请人：TULARIK INC

  公开号：WO2003002062A2

  公开（公告）日：2003-01-09

  Compounds, compositions and methods are provided that are useful in the treatment or prevention of a condition or disorder mediated by an uncoupling protein. In particular, the compounds of the invention modulate the expression and/or activity of UCP3. The subject compositions are particularly useful in the treatment of obesity and type II diabetes, and associated diseases.
• Novel Thiazole-Based Heterocycles as Selective Inhibitors of Fibrinogen-Mediated Platelet Aggregation
  作者：Pauline J. Sanfilippo、Patricia Andrade-Gordon、Maud J. Urbanski、Kimberly N. Beers、Annette Eckardt、Robert Falotico、Mark H. Ginsberg、Steve Offord、Jeffrey B. Press

  DOI：10.1021/jm00001a008

  日期：1995.1

  The synthesis and biological activity of novel thiazole-based heterocycles as inhibitors of thrombin-induced human platelet aggregation are described. Further evaluation of selected compounds show they inhibit platelet aggregation as stimulated by a variety of agonists. The more active compounds also were found to inhibit fibrinogen binding to platelets. To further delineate the mechanism of action of these compounds, direct binding studies with the purified glycoprotein (GP) IIb/IIIa receptor were performed. Flow cytometry analyses of 24 and 32 indicate that these compounds block the activation process of the GPIIb/IIIa receptor without denaturing the integrin receptor. On the basis of these studies, 32 exhibited the best profile as a novel nonpeptide inhibitor of fibrinogen-mediated platelet aggregation.